Business News • PR NewsWire • Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol

Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol

Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol

NORTH CHICAGO, Ill., June 26, 2020 /PRNewswire/ -- Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S....

View More : https://www.prnewswire.com:443/news-releases/allergan-an-abbvie-company-and-molecular-partners-receive-complete-response...

Releted News by prnewswire

NSW to Host FIFA Women's Football World Cup 2023(TM) Matches

Tune In Tomorrow - Global Citizen And The European Commission's 'Global Goal: Unite For Our Future'; Global Goal: Unite For Our Future-The Concert Broadcast Special To Premiere Tomorrow, Saturday, June 27, 2020 Following Global Goal: Unite For Our Future-The Summit

Big Brothers Big Sisters of America Awards Outstanding Volunteers and Youth in Mentoring Program

Far Point Provides Update on Global Blue Legal Action to Enforce PIPE Investment Agreements after Assertion of Failure of Condition from Two PIPE Investors